{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:56:37Z","timestamp":1791194197383,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"33","license":[{"start":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T00:00:00Z","timestamp":1324252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T00:00:00Z","timestamp":1324252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2012,8,16]]},"DOI":"10.1038\/onc.2011.537","type":"journal-article","created":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T11:57:32Z","timestamp":1324295852000},"page":"3754-3763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":209,"title":["Transtumoral targeting enabled by a novel neuropilin-binding peptide"],"prefix":"10.1038","volume":"31","author":[{"given":"L","family":"Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Agemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V R","family":"Kotamraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Teesalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K N","family":"Sugahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hamzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Ruoslahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,19]]},"reference":[{"key":"BFonc2011537_CR1","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1182\/blood-2007-08-110205","volume":"111","author":"LM Acevedo","year":"2008","unstructured":"Acevedo LM, Barillas S, Weis SM, Gothert JR, Cheresh DA . (2008). Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 111: 2674\u20132680.","journal-title":"Blood"},{"key":"BFonc2011537_CR2","doi-asserted-by":"publisher","first-page":"17450","DOI":"10.1073\/pnas.1114518108","volume":"108","author":"L Agemy","year":"2011","unstructured":"Agemy L, Friedmann-Morvinski D, Kotamraju VR, Roth L, Sugahara KN, Girard OM et al. (2011). Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci USA 108: 17450\u201317455.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2011537_CR3","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/blood-2010-03-274258","volume":"116","author":"L Agemy","year":"2010","unstructured":"Agemy L, Sugahara KN, Kotamraju VR, Gujraty K, Girard OM, Kono Y et al. (2010). Nanoparticle-induced vascular blockade in human prostate cancer. Blood 116: 2847\u20132856.","journal-title":"Blood"},{"key":"BFonc2011537_CR4","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1158\/1078-0432.CCR-08-0563","volume":"15","author":"A Bagri","year":"2009","unstructured":"Bagri A, Tessier-Lavigne M, Watts RJ . (2009). Neuropilins in tumor biology. Clin Cancer Res 15: 1860\u20131864.","journal-title":"Clin Cancer Res"},{"key":"BFonc2011537_CR5","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1161\/01.RES.0000171756.13554.49","volume":"96","author":"PM Becker","year":"2005","unstructured":"Becker PM, Waltenberger J, Yachechko R, Mirzapoiazova T, Sham JS, Lee CG et al. (2005). Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circ Res 96: 1257\u20131265.","journal-title":"Circ Res"},{"key":"BFonc2011537_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2008.01.029","volume":"13","author":"M Caunt","year":"2008","unstructured":"Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK et al. (2008). Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13: 331\u2013342.","journal-title":"Cancer Cell"},{"key":"BFonc2011537_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0896-6273(00)80371-2","volume":"19","author":"H Chen","year":"1997","unstructured":"Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M . (1997). Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 19: 547\u2013559.","journal-title":"Neuron"},{"key":"BFonc2011537_CR8","doi-asserted-by":"publisher","first-page":"8052","DOI":"10.1158\/1078-0432.CCR-08-1520","volume":"14","author":"NA Dallas","year":"2008","unstructured":"Dallas NA, Gray MJ, Xia L, Fan F, van Buren 2nd G, Gaur P et al. (2008). Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin Cancer Res 14: 8052\u20138060.","journal-title":"Clin Cancer Res"},{"key":"BFonc2011537_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1158\/1535-7163.MCT-05-0538","volume":"5","author":"LM Ellis","year":"2006","unstructured":"Ellis LM . (2006). The role of neuropilins in cancer. Mol Cancer Ther 5: 1099\u20131107.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2011537_CR10","doi-asserted-by":"publisher","first-page":"7210","DOI":"10.1158\/0008-5472.CAN-07-6752","volume":"68","author":"V Fogal","year":"2008","unstructured":"Fogal V, Zhang L, Krajewski S, Ruoslahti E . (2008). Mitochondrial\/cell-surface protein p32\/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68: 7210\u20137218.","journal-title":"Cancer Res"},{"key":"BFonc2011537_CR11","doi-asserted-by":"publisher","first-page":"18040","DOI":"10.1074\/jbc.M909259199","volume":"275","author":"Z Gluzman-Poltorak","year":"2000","unstructured":"Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G . (2000). Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem 275: 18040\u201318045.","journal-title":"J Biol Chem"},{"key":"BFonc2011537_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/10611860701539584","volume":"15","author":"K Greish","year":"2007","unstructured":"Greish K . (2007). Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 15: 457\u2013464.","journal-title":"J Drug Target"},{"key":"BFonc2011537_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2004.12.047","volume":"231","author":"N Guttmann-Raviv","year":"2006","unstructured":"Guttmann-Raviv N, Kessler O, Shraga-Heled N, Lange T, Herzog Y, Neufeld G . (2006). The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett 231: 1\u201311.","journal-title":"Cancer Lett"},{"key":"BFonc2011537_CR14","doi-asserted-by":"publisher","first-page":"7154","DOI":"10.1073\/pnas.1104540108","volume":"108","author":"J Hamzah","year":"2011","unstructured":"Hamzah J, Kotamraju VR, Seo JW, Agemy L, Fogal V, Mahakian LM et al. (2011). Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 108: 7154\u20137159.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2011537_CR15","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1021\/bi101662j","volume":"50","author":"N Haspel","year":"2011","unstructured":"Haspel N, Zanuy D, Nussinov R, Teesalu T, Ruoslahti E, Aleman C . (2011). Binding of a C-end rule peptide to the neuropilin-1 receptor: a molecular modeling approach. Biochemistry 50: 1755\u20131762.","journal-title":"Biochemistry"},{"key":"BFonc2011537_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0092-8674(00)80534-6","volume":"90","author":"Z He","year":"1997","unstructured":"He Z, Tessier-Lavigne M . (1997). Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 90: 739\u2013751.","journal-title":"Cell"},{"key":"BFonc2011537_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin CH, Rubin K, Pietras K, Ostman A . (2004). High interstitial fluid pressure -- an obstacle in cancer therapy. Nat Rev Cancer 4: 806\u2013813.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2011537_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1535-6108(03)00273-3","volume":"4","author":"JA Hoffman","year":"2003","unstructured":"Hoffman JA, Giraudo E, Singh M, Zhang L, Inoue M, Porkka K et al. (2003). Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4: 383\u2013391.","journal-title":"Cancer Cell"},{"key":"BFonc2011537_CR19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes RO . (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110: 673\u2013687.","journal-title":"Cell"},{"key":"BFonc2011537_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/annurev.bioeng.1.1.241","volume":"1","author":"RK Jain","year":"1999","unstructured":"Jain RK . (1999). Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1: 241\u2013263.","journal-title":"Annu Rev Biomed Eng"},{"key":"BFonc2011537_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.nano.2008.07.007","volume":"5","author":"PP Karmali","year":"2009","unstructured":"Karmali PP, Kotamraju VR, Kastantin M, Black M, Missirlis D, Tirrell M et al. (2009). Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 5: 73\u201382.","journal-title":"Nanomedicine"},{"key":"BFonc2011537_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0092-8674(00)80535-8","volume":"90","author":"AL Kolodkin","year":"1997","unstructured":"Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD . (1997). Neuropilin is a semaphorin III receptor. Cell 90: 753\u2013762.","journal-title":"Cell"},{"key":"BFonc2011537_CR23","doi-asserted-by":"publisher","first-page":"9381","DOI":"10.1073\/pnas.0403317101","volume":"101","author":"P Laakkonen","year":"2004","unstructured":"Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T et al. (2004). Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA 101: 9381\u20139386.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2011537_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nm720","volume":"8","author":"P Laakkonen","year":"2002","unstructured":"Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E . (2002). A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 8: 751\u2013755.","journal-title":"Nat Med"},{"key":"BFonc2011537_CR25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jmb.2006.11.021","volume":"366","author":"WC Liang","year":"2007","unstructured":"Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y et al. (2007). Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 366: 815\u2013829.","journal-title":"J Mol Biol"},{"key":"BFonc2011537_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10456-005-9009-6","volume":"8","author":"R Mamluk","year":"2005","unstructured":"Mamluk R, Klagsbrun M, Detmar M, Bielenberg DR . (2005). Soluble neuropilin targeted to the skin inhibits vascular permeability. Angiogenesis 8: 217\u2013227.","journal-title":"Angiogenesis"},{"key":"BFonc2011537_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2006.10.018","volume":"11","author":"Q Pan","year":"2007","unstructured":"Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N et al. (2007). Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11: 53\u201367.","journal-title":"Cancer Cell"},{"key":"BFonc2011537_CR28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/smll.200801789","volume":"5","author":"JH Park","year":"2009","unstructured":"Park JH, von Maltzahn G, Zhang L, Derfus AM, Simberg D, Harris TJ et al. (2009). Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 5: 694\u2013700.","journal-title":"Small"},{"key":"BFonc2011537_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc724","volume":"2","author":"E Ruoslahti","year":"2002","unstructured":"Ruoslahti E . (2002a). Specialization of tumour vasculature. Nat Rev Cancer 2: 83\u201390.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2011537_CR30","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S1359-6446(02)02501-1","volume":"7","author":"E Ruoslahti","year":"2002","unstructured":"Ruoslahti E . (2002b). Drug targeting to specific vascular sites. Drug Discov Today 7: 1138\u20131143.","journal-title":"Drug Discov Today"},{"key":"BFonc2011537_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1083\/jcb.200910104","volume":"188","author":"E Ruoslahti","year":"2010","unstructured":"Ruoslahti E, Bhatia SN, Sailor MJ . (2010). Targeting of drugs and nanoparticles to tumors. J Cell Biol 188: 759\u2013768.","journal-title":"J Cell Biol"},{"key":"BFonc2011537_CR32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M . (1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735\u2013745.","journal-title":"Cell"},{"key":"BFonc2011537_CR33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","volume":"16","author":"KN Sugahara","year":"2009","unstructured":"Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM et al. (2009). Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16: 510\u2013520.","journal-title":"Cancer Cell"},{"key":"BFonc2011537_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1183057","volume":"328","author":"KN Sugahara","year":"2010","unstructured":"Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR et al. (2010). Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328: 1031\u20131035.","journal-title":"Science"},{"key":"BFonc2011537_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0012-1606(87)90335-6","volume":"122","author":"S Takagi","year":"1987","unstructured":"Takagi S, Tsuji T, Amagai T, Takamatsu T, Fujisawa H . (1987). Specific cell surface labels in the visual centers of Xenopus laevis tadpole identified using monoclonal antibodies. Dev Biol 122: 90\u2013100.","journal-title":"Dev Biol"},{"key":"BFonc2011537_CR36","doi-asserted-by":"publisher","first-page":"16157","DOI":"10.1073\/pnas.0908201106","volume":"106","author":"T Teesalu","year":"2009","unstructured":"Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E . (2009). C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 106: 16157\u201316162.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2011537_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10439-005-9002-7","volume":"34","author":"DL Thorek","year":"2006","unstructured":"Thorek DL, Chen AK, Czupryna J, Tsourkas A . (2006). Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 34: 23\u201338.","journal-title":"Ann Biomed Eng"},{"key":"BFonc2011537_CR38","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1021\/nn102863y","volume":"5","author":"M Uchida","year":"2011","unstructured":"Uchida M, Kosuge H, Terashima M, Willits DA, Liepold LO, Young MJ et al. (2011). Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano 5: 2493\u20132502.","journal-title":"ACS Nano"},{"key":"BFonc2011537_CR39","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1021\/bc800077y","volume":"19","author":"G von Maltzahn","year":"2008","unstructured":"von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, Jayakumar J et al. (2008). In vivo tumor cell targeting with \u2018click\u2019 nanoparticles. Bioconjug Chem 19: 1570\u20131578.","journal-title":"Bioconjug Chem"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2011537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2011537","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2011537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T18:08:56Z","timestamp":1647886136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2011537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,19]]},"references-count":39,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2012,8,16]]}},"alternative-id":["BFonc2011537"],"URL":"https:\/\/doi.org\/10.1038\/onc.2011.537","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,19]]},"assertion":[{"value":"3 September 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}